Cargando…

Hydroxysafflor Yellow A Ameliorates Renal Fibrosis by Suppressing TGF-β1-Induced Epithelial-to-Mesenchymal Transition

OBJECTIVE: Renal fibrosis is the common pathological foundation of many chronic kidney diseases (CKDs). The aim of this study was to investigate whether Hydroxysafflor yellow A (HSYA) can preserve renal function by inhibiting the progression of renal fibrosis and the potential mechanisms. METHODS: R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Naping, Duan, Jialin, Li, Huihui, Wang, Yanhua, Wang, Fang, Chu, Jianjie, Sun, Jin, Liu, Meiyou, Wang, Chao, Lu, Chengtao, Wen, Aidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835075/ https://www.ncbi.nlm.nih.gov/pubmed/27088510 http://dx.doi.org/10.1371/journal.pone.0153409

Ejemplares similares

Hydroxysafflor Yellow A Phytosomes Administered via Intervaginal Space Injection Ameliorate Pulmonary Fibrosis in Mice
por: Li, Tingting, et al.
Publicado: (2022)

Hydroxysafflor Yellow A Ameliorates Myocardial Ischemia/Reperfusion Injury by Suppressing Calcium Overload and Apoptosis
por: Ye, Jingxue, et al.
Publicado: (2021)

Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
por: Jia, Lining, et al.
Publicado: (2015)

Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway
por: HU, TIANXIN, et al.
Publicado: (2016)

Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway
por: Hu, Tianxin, et al.
Publicado: (2021)

Nanoemulsions of Hydroxysafflor Yellow A for Enhancing Physicochemical and In Vivo Performance
por: Zhang, Yingjie, et al.
Publicado: (2023)

Therapeutic Potential of Hydroxysafflor Yellow A on Cardio-Cerebrovascular Diseases
por: Bai, Xue, et al.
Publicado: (2020)

Establishment of Fluorescence Sensitization Method for Hydroxysafflor Yellow A
por: Haiyan, CAO, et al.
Publicado: (2020)

Synergistic neuroprotective effects of Danshensu and hydroxysafflor yellow A on cerebral ischemia-reperfusion injury in rats
por: Xu, Hang, et al.
Publicado: (2017)

Superior Stability of Hydroxysafflor Yellow A in Xuebijing Injection and the Associated Mechanism
por: Pu, Weiling, et al.
Publicado: (2017)

Antioxidant effects of hydroxysafflor yellow A and acetyl-11-keto-β-boswellic acid in combination on isoproterenol-induced myocardial injury in rats
por: CHEN, MINCHUN, et al.
Publicado: (2016)

Antioxidant effects of hydroxysafflor yellow A and acetyl-11-keto-β-boswellic acid in combination on isoproterenol-induced myocardial injury in rats
por: Chen, Minchun, et al.
Publicado: (2022)

Restorative effects of hydroxysafflor yellow A on hepatic function in an experimental regression model of hepatic fibrosis induced by carbon tetrachloride
por: Li, Yanuo, et al.
Publicado: (2017)

Neuroprotection of hydroxysafflor yellow A in experimental cerebral ischemia/reperfusion injury via metabolic inhibition of phenylalanine and mitochondrial biogenesis
por: Chen, Suning, et al.
Publicado: (2019)

Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF-κB signaling pathway
por: Bai, Juan, et al.
Publicado: (2018)

Hydroxysafflor Yellow A Attenuates Lipopolysaccharide-Induced Neurotoxicity and Neuroinflammation in Primary Mesencephalic Cultures
por: Wang, Tian, et al.
Publicado: (2018)

Hydroxysafflor Yellow A Suppresses MRC-5 Cell Activation Induced by TGF-β1 by Blocking TGF-β1 Binding to TβRII
por: Pan, Ruiyan, et al.
Publicado: (2017)

Hydroxysafflor yellow A protects against angiotensin II-induced hypertrophy
por: Ni, Bin, et al.
Publicado: (2018)

Mechanism of hydroxysafflor yellow A on acute liver injury based on transcriptomics
por: Hou, Xiangmei, et al.
Publicado: (2022)

Protective effect of hydroxysafflor yellow A on MSCs against senescence induced by d-galactose
por: Song, Xiaoqing, et al.
Publicado: (2022)

Hydroxysafflor Yellow A Protects Neurons From Excitotoxic Death through Inhibition of NMDARs
por: Wang, Xingtao, et al.
Publicado: (2016)

Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells
por: Guo, Xinjing, et al.
Publicado: (2018)

Hydroxysafflor yellow A attenuates the expression of inflammatory cytokines in acute soft tissue injury
por: Dong, Fang, et al.
Publicado: (2017)

Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells
por: Pan, Qin, et al.
Publicado: (2015)

Hydroxysafflor Yellow A protects spinal cords from ischemia/reperfusion injury in rabbits
por: Shan, Le-qun, et al.
Publicado: (2010)

Hydroxysafflor yellow A inhibits endothelial cell ferroptosis in diabetic atherosclerosis mice by regulating miR-429/SLC7A11
por: Rong, Jianjie, et al.
Publicado: (2023)

Astragaloside and/or Hydroxysafflor Yellow A Attenuates Oxygen-Glucose Deprivation-Induced Cultured Brain Microvessel Endothelial Cell Death through Downregulation of PHLPP-1
por: Cao, Jinyi, et al.
Publicado: (2020)

Hydroxysafflor yellow A improved retinopathy via Nrf2/HO-1 pathway in rats
por: Sun, Zhihui, et al.
Publicado: (2022)

Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury
por: Wang, Yang, et al.
Publicado: (2016)

Chrysin Ameliorates Cyclosporine-A-Induced Renal Fibrosis by Inhibiting TGF-β(1)-Induced Epithelial–Mesenchymal Transition
por: Nagavally, Rohan Reddy, et al.
Publicado: (2021)

Protective effect of hydroxysafflor yellow A on cyclosporin A-induced renal oxidative stress in vitro and in vivo
por: Wang, Jiyuan, et al.
Publicado: (2022)

Proteomic investigation of effects of hydroxysafflor yellow A in oxidized low-density lipoprotein-induced endothelial injury
por: Ye, Feng, et al.
Publicado: (2017)

Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases
por: Ao, Hui, et al.
Publicado: (2018)

Hydroxysafflor Yellow A Shows Protection against PPARγ Inactivation in Nitrosative Neurons
por: Sun, Li, et al.
Publicado: (2018)

Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats
por: Han, Xiaotong, et al.
Publicado: (2016)

Polydatin ameliorates pulmonary fibrosis by suppressing inflammation and the epithelial mesenchymal transition via inhibiting the TGF-β/Smad signaling pathway
por: Qiu, Yue, et al.
Publicado: (2019)

Hydroxysafflor Yellow A Together with Blood–Brain Barrier Regulator Lexiscan for Cerebral Ischemia Reperfusion Injury Treatment
por: Tan, Liwei, et al.
Publicado: (2020)

Hydroxysafflor Yellow A Attenuates the Apoptosis of Peripheral Blood CD4(+) T Lymphocytes in a Murine Model of Sepsis
por: Wang, Jinping, et al.
Publicado: (2017)

Metabolomics reveals the effects of hydroxysafflor yellow A on neurogenesis and axon regeneration after experimental traumatic brain injury
por: Hu, En, et al.
Publicado: (2023)

Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer
por: O’Connor, Joseph W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5507upegespmonlemnvkj9uchb